WATERTOWN, Mass., July 27, 2026
Neumora Therapeutics announced positive preclinical toxicology results for NMRA-215, its investigational brain-penetrant oral NLRP3 inhibitor being developed for the treatment of obesity and cardiometabolic diseases. Following the successful completion of a repeat 13-week toxicology study in rats, the company confirmed its plans to submit an Investigational New Drug (IND) application in the fourth quarter of 2026 and initiate a Phase 1 clinical trial before the end of the year. The repeat study found no unexpected in-life adverse findings, strengthening confidence in the candidate after an earlier study raised concerns that were later linked to study-related discrepancies rather than the drug itself. This milestone reinforces Neumora’s commitment to advancing innovative therapies targeting significant unmet medical needs in metabolic disease.
Repeat Toxicology Study Strengthens Development Path
The latest 13-week repeat toxicology study, involving 162 rats, demonstrated no unexpected safety findings, providing strong evidence that the adverse events reported in an earlier study were not associated with NMRA-215. After initiating a for-cause audit, Neumora identified multiple critical discrepancies in the previous study, prompting the repeat evaluation. Combined with favorable findings from 28-day rat, 28-day dog, and 13-week dog toxicology studies, the updated safety package supports continued clinical advancement. Based on these comprehensive data, the company is moving forward with regulatory preparations and remains on track for IND submission in Q4 2026, marking an important step toward bringing the investigational therapy into human clinical testing.
NMRA-215 Shows Promise for Obesity and Cardiometabolic Disorders
NMRA-215 is designed as a potentially best-in-class oral NLRP3 inhibitor capable of achieving high brain penetration and sustained inhibition of inflammatory pathways linked to obesity. Preclinical studies demonstrated significant weight loss as a standalone treatment, including effects comparable to incretin-based therapies, while also showing additional weight reduction when combined with semaglutide. Researchers also observed improvements in cardiometabolic biomarkers, highlighting the therapy’s potential to reduce cardiovascular risk factors associated with obesity. By targeting NLRP3-mediated neuroinflammation in the hypothalamus, NMRA-215 aims to regulate appetite-related neuronal pathways and decrease food intake, offering a differentiated mechanism that could provide long-term benefits for patients with obesity and metabolic disorders.
Advertisement
Company Targets Clinical Advancement by End of 2026
According to Neumora Therapeutics, the encouraging toxicology results and compelling preclinical efficacy data support continued investment in NMRA-215 as a novel treatment candidate. Company leadership emphasized that the molecule’s unique pharmacological profile, combined with its ability to deliver sustained brain exposure and meaningful metabolic improvements, positions it as a promising therapy for obesity and related cardiometabolic diseases. With IND submission planned for the fourth quarter of 2026 and a Phase 1 clinical trial expected to begin before year-end, Neumora is preparing to transition NMRA-215 from preclinical development into human studies. The advancement reflects the company’s broader strategy of developing innovative therapies targeting novel biological mechanisms to improve treatment outcomes for patients with high unmet medical needs.
Source: Neumora Therapeutics press release
